Login / Signup

Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study.

Nicolas DelanoyDebbie G J RobbrechtMario EisenbergerOliver SartorRonald de WitFlorence MercierChristine Geffriaud-RicouardJohann de BonoStephane Marie Oudard
Published in: Cancers (2021)
This post hoc analysis of the PROSELICA phase III study shows that pain progression at initiation of CABA in mCRPC patients previously treated with DOC is associated with a poor prognosis. Disease progression should be carefully monitored, even in the absence of PSA rise.
Keyphrases